Biography
Dr Liu is a Senior Research Fellow and Molecular Biologist with expertise in oxidative protein chemistry at University of Sydney. She was a Biochemistry Lecturer in Taipei Medical University Taiwan. Dr Liu completed MSc in Cell and Molecular Biology at Taipei Medical University Taiwan, followed by second MSc in Biotechnology, University of New South Wales. She then completed her PhD within the Department of Chemistry and Biomolecular Science, Macquarie University.
Dr Chia-Chi (Jat) Liu is an internationally recognised molecular biologist and Senior Research Fellow at the University of Sydney. She leads the Cardiac Membrane Biology Laboratory at the Kolling Medical Research Institute and collaborates as a Visiting Scholar at the Heart Research Institute.
A global authority and top 1% leader in Na⁺/K⁺-ATPase research, Dr Liu’s pioneering work has transformed understanding of how oxidative stress regulates this essential membrane pump, revealing pathways that link redox biology to heart disease and pregnancy complications such as preeclampsia. Her discoveries underpin a new therapeutic strategy targeting the β₃-adrenergic receptor pathway and have led to biomarker-guided diagnostics now advancing toward clinical translation.
Dr Liu has led more than 30 multidisciplinary projects, securing over $8 million in competitive funding, with publications in Circulation, Circulation Research, and the Journal of Clinical Investigation. She is the founder and scientific lead of NeoPre, developing a simple, low-cost urine test for early detection of preeclampsia, and is currently leading investigator-initiated clinical trials of β₃-adrenergic receptor agonists for preeclampsia treatment.
Her contributions have been recognised with numerous awards, including the 2025–2026 and 2022 Heart Research Australia Project Awards, the 2024 IMPACT Philanthropy Award, Ramsay Research and Teaching Fund, National Heart Foundation Postdoctoral Fellowship, and multiple travel and career development awards from the University of Sydney and the Kolling Institute.
Driven by a passion for equitable
innovation, Dr Liu’s vision is to translate cutting-edge molecular science into
practical diagnostic and therapeutic solutions that improve maternal and
cardiovascular health worldwide.
